Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of harmful effects in non-randomised studies

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Storebø, Ole Jakob ^a,b,c   Pedersen, Nadia ^b   Ramstad, Erica ^a,b   Krogh, Helle B ^a,b   Moreira Maia, Carlos R ^d   Magnusson, Frederik L ^b   Holmskov, Mathilde ^b   Nilausen, Trine Danvad ^b   Skoog, Maria ^e   Rosendal, Susanne ^f   Groth, Camilla ^g   Gillies, Donna ^h   Buch Rasmussen, Kirsten ^b   Gauci, Dorothy ⁱ   Zwi, Morris ^j   Kirubakaran, Richard ^k   Forsbøl, Bente ^l   Håkonsen, Sasja J ^m   Aagaard, Lise ⁿ   Simonsen, Erik ^b   Gluud, Christian ^e   more..

^a Psychiatric Research Unit   (Denmark)

^b Psychiatric Research Unit   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e Rigshospitalet   (Denmark)

^f Psychiatric Centre North Zealand   (Denmark)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h CUMBERLAND HOSPITAL   (Australia)

ⁱ DEPARTMENT OF HEALTH   (Malta)

^j WHITTINGTON HOSPITAL NHS TRUST   (United Kingdom)

^k CHRISTIAN MEDICAL COLLEGE   (India)

^l Child and Adolescent Psychiatric Clinic   (Denmark)

^m AALBORG UNIVERSITY   (Denmark)

ⁿ UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT DISEASE; ATTENTION DEFICIT DISORDER; CASE CONTROL STUDY; CASE STUDY; CHILDHOOD DISEASE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GROUPS BY AGE; HUMAN; MEDICATION COMPLIANCE; META ANALYSIS; PRIORITY JOURNAL; PUBLISHING; REVIEW; SEX DIFFERENCE; SOCIOECONOMICS; SYSTEMATIC REVIEW;

EID: 84969560131     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012069     Document Type: Review

References (101)

1. Aagaard L, Hansen EH. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs. BMC Clinical Pharmacology 2009;9:4. [DOI: 10.1186/1472-6904-9-4]
2. American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128(5):1077-22.
3. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. Journal of Clinical Epidemiology 2013;66(7):719-25. [DOI: 10.1016/j.jclinepi.2012.03.013]
4. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation - determinants of a recommendation's direction and strength. Journal of Clinical Epidemiology 2013;66(7):726-35. [DOI: 10.1016/j.jclinepi.2013.02.003]
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd Edition. Washington, DC: American Psychiatric Association, 1980.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM III-R). 3rd Edition. Washington, DC: American Psychiatric Association, 1987.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Text revision (DSM-IV-TR). 4th Edition. Washington, DC: American Psychiatric Association, 2000.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th Edition. Washington, DC: American Psychiatric Association, 2013.
10. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [DOI: 10.1016/j.jclinepi.2010.07.015]
11. Barkley RA. A review of stimulant drug research with hyperactive children. Journal of Child Psychology and Psychiatry 1977;18(2):137-65. [DOI: 10.1111/j.1469-7610.1977.tb00425.x]
12. Barkley RA. The use of psychopharmacology to study reciprocal influences in parent-child interaction. Journal of Abnormal Child Psychology 1981;9(3):303-10. [PUBMED: 7320347]
13. Barkley RA. Hyperactive girls and boys: stimulant drug effects on mother-child interactions. Journal of Child Psychology and Psychiatry 1989;30(3):379-90. [DOI: 10.1111/j.1469-7610.1989.tb00253.x]
14. Barkley RA, DuPaul GJ, McMurray MB. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics 1991;87(4):519-31. [PUBMED: 2011430]
15. Bhutta AT, Cleves MA, Casey PH, Cradock MM, Anand KJ. Cognitive and behavioral outcomes of school-aged children who were born preterm: a meta-analysis. JAMA 2002;288(6):728-37. [PUBMED: 12169077]
16. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Journal of Clinical Psychiatry 2003;64(Suppl 11):3-8. [PUBMED: 14529323]
17. Bolea-Alamañac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacoly 2014;28(3):179-203.
18. Brunetti M, Shemilt I, Pregno S, Vale L, Oxman AD, Lord J, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. Journal of Clinical Epidemiology 2013;66(2):140-50. [DOI: 10.1016/j.jclinepi.2012.04.012]
19. Burnett A, Davey CG, Wood SJ, Wilson-Ching M, Molloy C, Cheong JLY, et al. Extremely preterm birth and adolescent mental health in a geographical cohort born in the 1990s. Psychological Medicine 2014;44(7):1533-44. [DOI: 10.1017/S0033291713002158]
20. Castellanos FX, Sonuga-Barke EJS, Milham MP, Tannock R. Characterizing cognition in ADHD: beyond executive dysfunction. Trends in Cognitive Sciences 2006;10(3):117-23. [DOI: 10.1016/j.tics.2006.01.011]
21. Catalá-López F, Ridao M, Sanfélix-Gimenob G, Peiró S. Cost-effectiveness of pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: qualitative synthesis of scientific evidence [Coste-efectividad del tratamiento farmacológico del trastorno por déficit de atención e hiperactividad en niños y adolescentes: síntesis cualitativa de la evidencia científica]. Revista de Psiquiatría y Salud Mental 2013;6(4):168-77. [DOI: 10.1016/j.rpsm.2012.12.002]
22. ¶ 2011-2014. Morbidity and Mortality Weekly Report 2015;64(40):1156. [PUBMED: 26469562]
23. Connor DF. Preschool attention deficit hyperactivity disorder: a review of prevalence, diagnosis, neurobiology, and stimulant treatment. Journal of Developmental and Behavioral Pediatrics 2002;23(Suppl 1):S1-9. [PUBMED: 11875284]
24. Cortese S, Moreira-Maia CR, St. Fleur D, Morcillo-Peñalver C, Rohde LA, Faraone SV. Association between ADHD and obesity: a systematic review and meta-analysis. American Journal of Psychiatry 2016;173(1):34-43. [DOI: 10.1176/appi.ajp.2015.15020266]
25. Cox DJ, Merkel RL, Penberthy JK, Kovatchev B, Hankin CS. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 2004;43(3):269-75. [PUBMED: 15076259]
26. Czamara D, Tiesler CM, Kohlböck G, Berdel D, Hoffmann B, Bauer CP, et al. Children with ADHD symptoms have a higher risk for reading, spelling and math difficulties in the GINIplus and LISAplus cohort studies. PLoS One 2013;8(5):e63859. [DOI: 10.1371/journal.pone.0063859]
27. Dalsgaard S, Leckman JF, Mortensen PB, Nielsen HS, Simonsen M. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry 2015;2(8):702-9. [DOI: 10.1016/S2215-0366(15)00271-0]
28. Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015;385(9983):2190-6. [DOI: 10.1016/S0140-6736(14)61684-6]
29. Donnelly M, Haby MM, Carter R, Andrews G, Vos T. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder. Australian and New Zealand Journal of Psychiatry 2004;38(8):592-601. [PUBMED: 15298581]
30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [PUBMED: 9310563]
31. Elgen SK, Sommerfelt K, Leversen KT, Markestad T. Minor neurodevelopmental impairments are associated with increased occurrence of ADHD symptoms in children born extremely preterm. European Child and Adolescent Psychiatry 2015;24(4):463-70. [DOI: 1007/s00787-014-0597-9]
32. Engert V, Pruessner JC. Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate. Current Neuropharmacology 2008;6(4):322-8. [DOI: 10.2174/157015908787386069]
33. Evans SW, Pelham WE, Smith BH, Bukstein O, Gnagy EM, Greiner AR, et al. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Experimental and Clinical Psychopharmacology 2001;9(2):163-75. [PUBMED: 11518092]
34. McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org. GRADEpro GDT: GRADEpro Guideline Development Tool. 2015.
35. Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 2006;45(11):1284-93. [DOI: 10.1097/01.chi.0000235077.32661.61]
36. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [DOI: 10.1016/j.jclinepi.2010.04.026]
37. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400.
38. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence- study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [DOI: 10.1016/j.jclinepi.2010.07.017]
39. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [DOI: 10.1016/j.jclinepi.2011.01.012]
40. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [DOI: 10.1016/j.jclinepi.2011.03.017]
41. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [DOI: 10.1016/j.jclinepi.2011.04.014]
42. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6. [DOI: 10.1016/j.jclinepi.2011.06.004]
43. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151-7. [DOI: 10.1016/j.jclinepi.2012.01.006]
44. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72. [DOI: 10.1016/j.jclinepi.2012.01.012]
45. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles - continuous outcomes. Journal of Clinical Epidemiology 2013;66(2):173-83. [DOI: 10.1016/j.jclinepi.2012.08.001]
46. Heal DJ, Pierce DM. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 2006;20(9):713-38. [PUBMED: 16953648]
47. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
48. Hong J, Dilla T, Arellano J. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain. BMC Psychiatry 2009;9:15. [DOI: 10.1186/1471-244X-9-15]
49. Hong SB, Kim JW, Choi BS, Hong YC, Park EJ, Shin MS, et al. Blood manganese levels in relation to comorbid behavioral and emotional problems in children with attention-deficit/hyperactivity disorder. Psychiatry Research 2014;220(1-2):418-25. [PUBMED: 25064383]
50. Hong SB, Im MH, Kim JW, Park EJ, Shin MS, Kim BN, et al. Environmental lead exposure and attention deficit/hyperactivity disorder symptom domains in a community sample of South Korean school-age children. Environmental Health Perspectives 2015;123(3):271-6. [PUBMED: 25280233]
51. International Council for Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1) 1996. http://bit.ly/1R6G3kG (accessed 6 May 2011).
52. Indredavik MS, Vik T, Heyerdahl S, Kulseng S, Fayers P, Brubakk AM. Psychiatric symptoms and disorders in adolescents with low birth weight. Archives of Disease in Childhood. Fetal and Neonatal Edition 2004;89(5):F445-50. [DOI: 10.1136/adc.2003.038943]
53. Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry 2001;40(2):147-58. [DOI: 10.1097/00004583-200102000-00009]
54. Kadesjö B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. Journal of Child Psychology and Psychiatry and Allied Disciplines 2001;42(4):487-92. [DOI: 10.1111/1469-7610.00742]
55. Kadesjö B. [ADHD hos barn och vuxna]. ADHD in Children and Adults. Stockholm: Socialstyrelsen, 2002.
56. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clinical Pharmacokinetics 1999;37(6):457-70. [PUBMED: 10628897]
57. King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technology Assessment 2006;10(23):iii-iv, xiii-146. [DOI: 10.3310/hta10230]
58. Kovess V, Keyes KM, Hamilton A, Pez O, Bitfoi A, Koç C, et al. Maternal smoking and offspring inattention and hyperactivity: results from a cross-national European survey. European Child and Adolescent Psychiatry 2015;24(8):919-29. [DOI: 10.1007/s00787-014-0641-9]
59. Larsson H, Sariaslan A, Långström N, D'Onofrio B, Lichtenstein P. Family income in early childhood and subsequent attention deficit/hyperactivity disorder: a quasi-experimental study. Journal of Child Psychology and Psychiatry and Allied Disciplines 2014;55(5):428-35. [PUBMED: 24111650]
60. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700. [DOI: 10.1136/bmj.b2700]
61. Maia CR, Matte BC, Ludwig T, Rohde LA. Switching from methylphenidate immediate release to MPH-SODAS™ in attention-deficit/hyperactivity disorder. European Child and Adolescent Psychiatry 2008;17(3):133-42. [DOI: 10.1007/s00787-007-0647-7]
62. Maia CR, Cortese S, Caye A, Deakin TK, Polanczyk GV, Rohde LAP. Long-term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD: a systematic review and meta-analysis. Journal of Attention Disorders 2014 December 10 [Epub ahead of print].
63. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 2015;4(1):1-9. [DOI: 10.1186/2046-4053-4-1]
64. MTA Cooperation Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Archives of General Psychiatry 1999;56(12):1073-86. [DOI: 10.1001/archpsyc.56.12.1073]
65. Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology 2013;66(7):736-42.e5. [DOI: 10.1016/j.jclinepi.2013.02.004]
66. National Collaborating Centre for Mental Health (NCCMH) commissioned by the National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. www.nccmh.org.uk/downloads/ADHD/CG72FullGuideline.pdf (accessed 11 December 2015).
67. National Collaborating Centre for Mental Health (NCCMH) commissioned by the National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: the NICE guideline on diagnosis and management of ADHD in children, young people and adults. www.nice.org.uk/guidance/cg72/evidence/adhd-full-guideline-241963165 (accessed 10 December 2015).
68. Newcorn JH. Co-morbidity in adults with ADHD. CNS Spectrums 2008;13 Suppl 12:12-5. [DOI: 10.1017/S1092852900003199]
69. Nigg JT, Casey BJ. An integrative theory of attention-deficit/hyperactivity disorder based on the cognitive and affective neurosciences. Development and Psychopathology 2005;17(3):785-806. [DOI: 10.1017/S0954579405050376]
70. Obel C, Zhu JL, Olsen J, Breining S, Li J, Gronborg TK, et al. The risk of attention deficit hyperactivity disorder in children exposed to maternal smoking during pregnancy - a reexamination using a sibling design. Journal of Child Psychology and Psychiatry 2015 October 28 [Epub ahead of print]. [DOI: 10.1111/jcpp.12478]
71. Pasini A, Paloscia C, Alessandrelli R, Porfirio MC, Curatolo P. Attention and executive functions profile in drug naive ADHD subtypes. Brain and Development 2007;29(7):400-8. [PUBMED: 17207595]
72. Pliszka S, The AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(7):894-921. [PUBMED: 17581453]
73. Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Current Opinion in Psychiatry 2007;20(4):386-92. [PUBMED: 17551354]
74. Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. International Journal of Epidemiology 2014;43(2):434-42. [PUBMED: 24464188]
75. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
76. Rosa-Neto P, Lou HC, Cumming P, Pryds O, Karrebaek H, Lunding J, et al. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. NeuroImage 2005;25(3):868-76. [PUBMED: 15808987]
77. Scahill L, Schwab-Stone M. Epidemiology of ADHD in school-age children. Child and Adolescent Psychiatric Clinics of North America 2000;9(3):541-55. [PUBMED: 10944656]
78. Schachar RJ, Tannock R, Cunningham C, Corkum PV. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry 1997;36(6):754-63.
79. Schmidt S, Petermann F. Developmental psychopathology: attention deficit hyperactivity disorder (ADHD). BMC Psychiatry 2009;9:58. [DOI: 10.1186/1471-244X-9-58]
80. Schulz KP, Fan J, Bédard ACV, Clerkin SM, Ivanov I, Tang CY, et al. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder. Archives of General Psychiatry 2012;69(9):952-61. [DOI: 10.1001/archgenpsychiatry.2011.2053]
81. Schweitzer JB, Lee DO, Hanford RB, Zink CF, Ely TD, Tagamets MA, et al. Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biological Psychiatry 2004;56(8):597-606. [PUBMED: 15476690]
82. Sergeant JA, Geurts H, Huijbregts S, Scheres A, Oosterlaan J. The top and the bottom of ADHD: a neuropsychological perspective. Neuroscience and Biobehavioural Reviews 2003;27(7):583-92. [PUBMED: 14624803]
83. Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Medicine 2012;10:99. [DOI: 10.1186/1741-7015-10-99]
84. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behavioural Brain Research 1998;94(1):127-52. [DOI: 10.1016/S0166-4328(97)00175-7]
85. Sonuga-Barke EJS, Coghill D, Markowitz JS, Swanson JM, Vandenberghe M, Hatch SJ. Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. Journal of American Academy of Child and Adolescent Psychiatry 2007;46(6):701-10. [DOI: 10.1097/chi.0b013e31804659f1]
86. Sterne JAC, Higgins JPT, Reeves BC, on behalf of the development group for ACROBAT-NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non-Randomised Studies of Interventions (ACROBAT-NRSI), Version 1.0.0, 24 September 2014. Available from http://www.riskofbias.info (accessed 25 May 2015).
87. Stevenson RD, Wolraich ML. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatric Clinics of North America 1989;36(5):1183-97. [PUBMED: 2677938]
88. Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews 2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2]
89. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs study). Pediatrics 2004;113(3 Pt 1):e206-16. [PUBMED: 14993578]
90. Swanson J. The MTA follow-up into adolescence: implications for personalized treatment. The International Society for Research in Child and Adolescent Psychopathology (ISRCAP); 2009 June 19, Seattle. 2009.
91. Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder-first upgrade. European Child and Adolescent Psychiatry 2004;13 Suppl 1:i7-i30.
92. U.S. Food, Drug Administration (FDA). Communication about an ongoing safety review of stimulant medications used in children with attention-deficit/hyperactivity disorder (ADHD). http://1.usa.gov/1M5AYoq (accessed 6 May 2011).
93. Van Lieshout RJ, Boyle MH, Saigal S, Morrison K, Schmidt LA. Mental health of extremely low birth weight survivors in their 30s. Pediatrics 2015;135(3):452-9. [PUBMED: 25667243]
94. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry 1998;155(10):1325-31. [PUBMED: 9766762]
95. Volkow ND, Wang GJ, Fowler JS, Telang F, Maynard L, Logan J, et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. American Journal of Psychiatry 2004;161(7):1173-80. [PUBMED: 15229048]
96. Volkow ND, Wang GJ, Tomasi D, Kollins SH, Wigal TL, Newcorn JH, et al. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. Journal of Neuroscience 2012;32(3):841-9. [PUBMED: 22262882]
97. World Health Organization. International Classification of Diseases, Ninth Revision, Volume 1. Geneva: World Health Organization 1977.
98. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.
99. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012;9(3):490-9. [DOI: 10.1007/s13311-012-0135-8]
100. Yang P, Chung LC, Chen CS, Chen CC. Rapid improvement in academic grades following methylphenidate treatment in attention-deficit hyperactivity disorder. Psychiatry and Clinical Neurosciences 2004;58(1):37-41. [PUBMED: 14678455]
101. Yoshimasu K, Barbaresi WJ, Colligan RC, Voigt RG, Killian JM, Weaver AL, et al. Childhood ADHD is strongly associated with a broad range of psychiatric disorders: a population-based birth cohort study. Journal of Child Psychology and Psychiatry and Allied Disciplines 2012;53(10):1036-43. [PUBMED: 22647074]